1. Abstract Title: The abstract title should not include results. All titles should be written in title case, and should not include a period at the end.
2. Abstract Body:
   • Abstracts must be properly formatted and organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
   • Abstracts should include a scientific hypothesis in the Purpose/Objectives section, and implications for research, policy or practice in the Conclusions section, when applicable.
   • The abstract cannot contain illustrations, images or graphs. If the abstract is accepted, presenters may include these items in their on-site presentations.
   • An abstract may contain one small table.
   • The maximum character limit, including the title and body of the abstract and any text in a table, is 2,600 characters. Spaces are not counted.
   • Institution names should not be included in the title or body of the abstract. Alternative language is “at one institution” or “a multi-institution” study, etc. This does not apply to cooperative research group names. 
3. Abstract Authors:
   • A maximum of 20 authors’ names may be listed on each abstract. There are no exceptions.
   • A Conflict of Interest Disclosure form must be submitted for each author. You can collect this information from the authors before you begin the submission.
   • The principal investigator (PI) should be listed as the final author on the abstract.
   • There is no mechanism for listing co-lead authors or co-PI’s.
   • Each author must have made substantial contributions to:
     • conception and design, or analysis and interpretation of data
     • drafting the abstract or revising it critically for important intellectual content
     • final approval of the version to be submitted/published
4. Use of Brand Names and Trade Names: Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices cannot be used in the title or body of the abstract. ASTRO reserves the right to replace proprietary names with generic names.
5. Track: The most appropriate track and subcategory for the abstract should be selected. Please note that the AM Scientific Committee Chairs have the authority to recategorize any abstract.
6. 提交费-Submission Fee: A $75 (USD) nonrefundable submission fee will be charged per abstract submitted. Payment is due at the time of submission. Payment must be rendered using a credit card.

1. Abstracts must be received by 11:59 p.m. Pacific time, Tuesday, March 12, 2024. Abstracts may be edited up until the deadline. Abstracts will be considered ineligible for review if they are incomplete. Abstracts that are unpaid or have payment issues will not be considered. If you do not receive a confirmation receipt, follow up with ASTRO to confirm your “complete” status.
2. Notifications: The person listed as Presenting Author will be notified via email of the disposition of the abstract by June 7, 2024. Abstract acceptance obligates the author to present the paper at the in-person meeting and pay the meeting registration fee. If circumstances prevent in-person meeting attendance, you must notify ASTRO and arrange for a co-author to present the abstract on your behalf.
3. Revisions: Please proof your abstract carefully for formatting, spelling and data errors. Pay special attention to the author order and presenting author designation. Review your confirmation email, as this is how the abstract will be published. You can make updates to your abstract until the submission deadline, March 12. After that date, errors can be corrected if sent to ASTRO by July 19, 2024. After this date, we cannot make any corrections. This rule is strictly enforced. Please note: Revisions should not be substantive and should not alter the results or the conclusions of the abstract. Revisions are meant only to correct errors that were made in the initial submission.
4. Withdrawals: If you choose to withdraw your abstract, please change your decision to “withdraw” in the Speaker Center by July 19, 2024 and notify ASTRO staff via email. After this date, your abstract will be published exactly as it was submitted in the International Journal of Radiation Oncology • Biology • Physics (Red Journal).
5. Submission of an abstract conveys permission to be posted online and printed in the International Journal of Radiation Oncology • Biology • Physics (Red Journal)
6. Late-breaking Abstracts: The late-breaking abstract submission site will open on June 26, 2024, and close July 12, 2024.

*Please note if you are an ASTRO member from a low or low middle income country as identified by the World Bank, you will receive a 50% discount off your corresponding registration rate if registering for the in-person full conference or virtual full conference packages.

*Please note if you are an ASTRO member from a low or low middle income country as identified by the World Bank, you will receive a 50% discount off your corresponding registration rate if registering for the in-person full conference or virtual full conference packages.